In: Vivet Therapeutics
Columbus close its third Investment Biotech Fund with 120€M
26/04/2021Read complete article here Read More
Vivet Therapeutics announces agreement with Mirum Pharmaceuticals
13/04/2021Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial... Read More
Vivet Therapeutics: FDA approved fase 1/2 study for VTX-801
19/11/2020PARIS / NEW YORK. November 2020 — Vivet Therapeutics, a gene therapy biotech company dedicated to developing treatments for inherited liver... Read More
Vivet and Pfizer: Gene Therapy for Wilson Disease
24/09/2020PARIS- NEW YORK,—September 23, 2020— Vivet Therapeutics, a privately held gene therapy biotech company dedicated to developing treatments for inherited liver... Read More
Vivet’s Product, VTX-803, receives US and EU Orphan Drug Designation
01/06/2020PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission... Read More
Pfizer secures exclusive option to acquire Vivet Therapeutics
20/03/2019Pfizer acquires 15% ownership stake in Vivet Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”),... Read More
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board
14/06/2018Paris, 12 June 2018- Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases today announced the…
Read MoreVivet Therapeutics named as one of the “Fierce 15” Biothec Companies of 2017 by FierceBiothec
03/10/2017Vivet Therapeutics is the only European Company that has been chosen as one of the “Fierce 15”, the final fifteen companies... Read More
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
04/05/2017Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases Paris,... Read More